Varenicline
"Varenicline" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A benzazepine derivative that functions as an ALPHA4/BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.
Descriptor ID |
D000068580
|
MeSH Number(s) |
D03.633.100.079.900 D03.633.100.857.942
|
Concept/Terms |
Varenicline- Varenicline
- 6,7,8,9-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)benzazepine
|
Below are MeSH descriptors whose meaning is more general than "Varenicline".
Below are MeSH descriptors whose meaning is more specific than "Varenicline".
This graph shows the total number of publications written about "Varenicline" by people in this website by year, and whether "Varenicline" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2009 | 0 | 1 | 1 | 2010 | 0 | 1 | 1 | 2012 | 0 | 3 | 3 | 2013 | 0 | 1 | 1 | 2014 | 0 | 1 | 1 | 2015 | 1 | 0 | 1 | 2016 | 1 | 0 | 1 | 2017 | 4 | 0 | 4 | 2020 | 0 | 2 | 2 | 2021 | 0 | 1 | 1 | 2022 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Varenicline" by people in Profiles.
-
Cinciripini PM, Kypriotakis G, Green C, Lawrence D, Anthenelli RM, Minnix J, Blalock JA, Beneventi D, Morris C, Karam-Hage M. The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial. Depress Anxiety. 2022 05; 39(5):429-440.
-
Rigotti NA, Kruse GR, Livingstone-Banks J, Hartmann-Boyce J. Treatment of Tobacco Smoking: A Review. JAMA. 2022 Feb 08; 327(6):566-577.
-
Fabbri A, Nejstgaard CH, Grundy Q, Bero L, Dunn AG, Mohammad A, Mintzes B. Association Between Conflicts of Interest and Authors' Positions on Harms of Varenicline: a Cross-Sectional Analysis. J Gen Intern Med. 2022 02; 37(2):290-297.
-
Parikh NS, Salehi Omran S, Kamel H, Elkind MSV, Willey JZ. Smoking-cessation pharmacotherapy for patients with stroke and TIA: Systematic review. J Clin Neurosci. 2020 Aug; 78:236-241.
-
Scoville EA, Tindle HA, Wells QS, Peyton SC, Gurwara S, Pointer SO, Horst SN, Schwartz DA, Adams DW, Freiberg MS, Gatskie V, King S, Abney LR, Beaulieu DB. Precision nicotine metabolism-informed care for smoking cessation in Crohn's disease: A pilot study. PLoS One. 2020; 15(3):e0230656.
-
Kress CM, Obi NU, Prochazka AV. In smokers with COPD, neither varenicline nor bupropion was linked to increased CV or neuropsychiatric risk vs NRT. Ann Intern Med. 2017 09 19; 167(6):JC31.
-
Littlewood RA, Claus ED, Wilcox CE, Mickey J, Arenella PB, Bryan AD, Hutchison KE. Moderators of smoking cessation outcomes in a randomized-controlled trial of varenicline versus placebo. Psychopharmacology (Berl). 2017 Dec; 234(23-24):3417-3429.
-
Bidwell LC, Karoly HC, Hutchison KE, Bryan AD. ADHD symptoms impact smoking outcomes and withdrawal in response to Varenicline treatment for smoking cessation. Drug Alcohol Depend. 2017 10 01; 179:18-24.
-
Wilcox CE, Calhoun VD, Rachakonda S, Claus ED, Littlewood RA, Mickey J, Arenella PB, Hutchison KE. Functional network connectivity predicts treatment outcome during treatment of nicotine use disorder. Psychiatry Res Neuroimaging. 2017 Jul 30; 265:45-53.
-
Wilcox CE, Claus ED, Calhoun VD, Rachakonda S, Littlewood RA, Mickey J, Arenella PB, Goodreau N, Hutchison KE. Default mode network deactivation to smoking cue relative to food cue predicts treatment outcome in nicotine use disorder. Addict Biol. 2018 01; 23(1):412-424.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|